Please provide your email address to receive an email when new articles are posted on . Khanani delved into tyrosine kinase inhibitors, including the SOL-1 and SOL-R trials evaluating OTX-TKI ...

Over 400 patients enrolled in Phase 3 trials for DURAVYU to treat wet AMD, with data expected in mid-2026. Delayed availability of topline data for LUGANO and LUCIA trials, with results expected in ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in treatment options for both dry and wet AMD. As highlighted by Huang and ...

The sponsor of two phase 3 clinical trials of an add-on agent to treat age-related macular degeneration has decided to halt both trials after they showed the add-on treatment did not outperform either ...

Donald Trump’s decision to let Nvidia and AMD export AI processors to China in exchange for a cut of their sales will have repercussions far beyond the U.S. The semiconductor supply chain is global, ...